|
| Status |
Public on Dec 31, 2016 |
| Title |
24h-response to bevacizumab erlortinib in non-small cell lung cancer from blood-based exon array profiling |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
The mechanisms of action of the combined targeted therapy bevacizumab erlotinib in late stage non-squamous non-small cell lung cancer was investigated by means of whole genome exon arrays.
mRNA from peripherial blood was extracted at baseline and 24h after initiation of the therapy and hybridized on Affymetrix Human Exon 1.0 ST Arrays
|
| |
|
| Overall design |
Prospective phase II trial investigating the efficacy and safety of bevacizumab erlotinib in non-small cell lung cancer
|
| |
|
| Contributor(s) |
Baty F, Brutsche M, Zappa F |
| Citation(s) |
28359318 |
| |
| Submission date |
Sep 23, 2014 |
| Last update date |
Apr 01, 2017 |
| Contact name |
Florent Baty |
| E-mail(s) |
florent.baty@kssg.ch
|
| Phone |
0041 71 494 2809
|
| Organization name |
Cantonal Hospital St. Gallen
|
| Department |
Lung Center
|
| Street address |
Rorschacherstrasse 95
|
| City |
St. Gallen |
| ZIP/Postal code |
9007 |
| Country |
Switzerland |
| |
|
| Platforms (1) |
| GPL5188 |
[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [probe set (exon) version] |
|
| Samples (86)
|
|
| Relations |
| BioProject |
PRJNA261816 |
Less...
More...